Antioxidants | |
Melatonin Therapy in Patients with Alzheimer’s Disease | |
Daniel P. Cardinali1  Daniel E. Vigo1  Natividad Olivar2  María F. Vidal2  | |
[1] Departamento de Docencia e Investigación, Facultad de Ciencias Médicas, Pontificia Universidad Católica Argentina, Buenos Aires 1007, Argentina; E-Mail:;Centro de Neuropsiquiatría y Neurología de la Conducta, Hospital de Clínicas “José de San Martín”, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires 1121, Argentina; E-Mails: | |
关键词: melatonin; Alzheimer’s disease; neurodegeneration; free radicals; oxidative stress; aging; mild cognitive impairment; melatonin analogs; | |
DOI : 10.3390/antiox3020245 | |
来源: mdpi | |
【 摘 要 】
Alzheimer’s disease (AD) is a major health problem and a growing recognition exists that efforts to prevent it must be undertaken by both governmental and non-governmental organizations. In this context, the pineal product, melatonin, has a promising significance because of its chronobiotic/cytoprotective properties potentially useful for a number of aspects of AD. One of the features of advancing age is the gradual decrease in circulating melatonin levels. A limited number of therapeutic trials have indicated that melatonin has a therapeutic value as a neuroprotective drug in the treatment of AD and minimal cognitive impairment (which may evolve to AD). Both
【 授权许可】
CC BY
© 2014 by the authors; licensee MDPI, Basel, Switzerland.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202003190027152ZK.pdf | 563KB | download |